On Tuesday local time, pharmaceutical giant Eli Lilly (LLY) saw its stock price rise to a record high, following optimistic commentary from J.P. Morgan (JPM) analysts, who raised their price target for the stock.
Eli Lilly is currently the world’s most valuable pharmaceutical company by market capitalization. Founded in 1876 by a chemist and federal veteran, the company later became the first to mass-produce insulin and polio vaccines. Its core product portfolio includes diabetes medications, weight-loss drugs, obesity treatments, and antidepressants such as Prozac. In April 2026, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s GLP-1 weight-loss drug Foundayo.
J.P. Morgan analyst Chris Schott reiterated an “Overweight” (i.e., Buy) rating on Eli Lilly’s stock and raised the price target from $1,300 to $1,400. Even after Tuesday’s gains, J.P. Morgan’s new target price implies that investors buying Eli Lilly shares at current levels could see potential returns of more than 13%.
The healthcare giant’s market capitalization has swelled to over $1.1 trillion, largely driven by the massive success of its blockbuster GLP-1 drugs Mounjaro and Zepbound. Schott predicts that rapid expansion in the U.S. weight-loss drug market, coupled with robust growth in international markets, will propel Eli Lilly’s sales and profits sharply higher. He expects the company to beat consensus earnings estimates when it reports second-quarter financial results on August 5.
The obesity drug market is poised for further expansion. On July 1, the new GLP-1 Bridge program made Zepbound and Foundayo available to eligible Medicare patients for as little as $50 per month. It is estimated that approximately 20 million Medicare patients may qualify for obesity drug use, suggesting that J.P. Morgan’s $1,400 price target could prove conservative.
Not all segments within the healthcare sector will grow at the same pace; some areas will grow much faster than others. The GLP-1 drug market is one of the areas currently booming and expected to maintain strong momentum well into the next decade. Eli Lilly is a leader in this segment. The company’s GLP-1 drugs, including the diabetes treatment Mounjaro and the two weight-loss drugs Zepbound and Foundayo, have posted strong sales performance. Thanks to its dominance in this field, Eli Lilly’s revenue and earnings growth over the past two years have significantly outpaced those of peers of comparable size.
Even as other companies seek to launch competitive therapies, Eli Lilly is well-positioned to consolidate its dominant position. The company boasts a deep pipeline of investigational products across its core therapeutic areas. More notably, some of its pipeline candidates are not expected to cannibalize its existing portfolio but rather to expand the market. Eli Lilly achieved this feat with Foundayo, an oral weight-loss drug that primarily attracts new patients. The company’s retatrutide, currently in Phase 3 clinical trials, may target individuals with high body mass index for whom current weight-loss options are insufficient. Retatrutide has already demonstrated efficacy comparable to bariatric surgery outcomes.
Beyond its diabetes and weight-loss drug pipeline, Eli Lilly has expanded its portfolio through acquisitions and is expected to make significant progress in other areas over the coming years. In addition, the company is increasingly leveraging artificial intelligence in drug discovery, a move that could help reduce expenses and boost profits over the long term.
Overall, Eli Lilly, with its leading position in the GLP-1 market, robust pipeline, and continuously expanding business footprint, has become a highly watched name in the healthcare sector. As the weight-loss drug market continues to grow, the company’s future growth prospects warrant close attention.
